Home » Stocks » AERI

Aerie Pharmaceuticals, Inc. (AERI)

Stock Price: $16.83 USD 0.01 (0.06%)
Updated May 11, 2021 10:22 AM EDT - Market open
Market Cap 798.77M
Revenue (ttm) 85.77M
Net Income (ttm) -175.94M
Shares Out 46.11M
EPS (ttm) -3.83
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 11
Last Price $16.83
Previous Close $16.82
Change ($) 0.01
Change (%) 0.06%
Day's Open 16.50
Day's Range 16.19 - 17.01
Day's Volume 69,742
52-Week Range 9.01 - 21.30

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Aerie (AERI) incurs a wider loss in the first quarter of 2021 and sales miss expectations.

4 days ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

5 days ago - Business Wire

Aerie (AERI) delivered earnings and revenue surprises of -4.35% and -1.64%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

5 days ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

5 days ago - Business Wire

Aerie (AERI) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 week ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

1 week ago - Business Wire

Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 week ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

1 week ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

1 week ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

3 weeks ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

1 month ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

1 month ago - Business Wire

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

1 month ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

1 month ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

2 months ago - Business Wire

Aerie (AERI) up more than 16% despite reporting a wider-than-expected loss in the fourth quarter of 2020. Revenues beat estimates.

2 months ago - Zacks Investment Research

Aerie (AERI) delivered earnings and revenue surprises of -5.33% and 13.49%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

2 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

2 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

2 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

4 months ago - Business Wire

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

5 months ago - Zacks Investment Research

Aerie (AERI) receives positive CHMP opinion for Roclanda for reduction of elevated intraocular pressure in adult patients.

5 months ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

5 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

6 months ago - Business Wire

Aerie Pharmaceuticals' (AERI) CEO Vince Anido on Q3 2020 Results - Earnings Call Transcript

6 months ago - Seeking Alpha

Aerie (AERI) reports a narrower-than-expected loss and revenues beat estimates in the third quarter of 2020.

6 months ago - Zacks Investment Research

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido On Q3 2020 Results - Quick Version Earnings Call Transcript

6 months ago - Seeking Alpha

Aerie (AERI) delivered earnings and revenue surprises of 19.75% and 4.43%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

6 months ago - Business Wire

Aerie (AERI) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

6 months ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

6 months ago - Business Wire

OSAKA, Japan & DURHAM, N.C.--(BUSINESS WIRE)--Santen Pharmaceutical Co., Ltd. (“Santen”) and Aerie Pharmaceuticals, Inc. (NASDAQ: AERI, “Aerie”) announced that Santen and Aerie have entered into an excl...

6 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

6 months ago - Business Wire

The FDA accepts Aerie's (AERI) investigational new drug application for AR-15512 eye drop for dry eye disease.

7 months ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies fo...

7 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), an ophthalmic pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for...

7 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

7 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

8 months ago - Business Wire

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

8 months ago - Zacks Investment Research

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q2 2020 Results - Earnings Call Transcript

9 months ago - Seeking Alpha

Aerie (AERI) posts a wider-than-expected loss and sales miss estimates in the second quarter of 2020.

9 months ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

9 months ago - Business Wire

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

9 months ago - Business Wire

Aerie (AERI) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

9 months ago - Zacks Investment Research

DURHAM, N.C.--(BUSINESS WIRE)--Aerie Pharmaceuticals, Inc.

9 months ago - Business Wire

Wall Street has given the eye-care specialist the cold shoulder in 2020. Is that an opportunity for individual investors?

10 months ago - The Motley Fool

Aerie has 2 marketed products and decent pipeline after a recent acquisition.

11 months ago - Seeking Alpha

Aerie (AERI) reported earnings 30 days ago. What's next for the stock?

11 months ago - Zacks Investment Research

Aerie Pharmaceuticals, Inc. (AERI) CEO Vicente Anido on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

About AERI

Aerie Pharmaceuticals, Inc., an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, ocular surface, and retinal diseases in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension; and Rocklatan, a once-daily fixed-dose combination of Rhopressa and latanopros to reduce IOP to treat patients with open-angle glaucoma. The company is al... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
IPO Date
Oct 25, 2013
CEO
Vicente Anido
Employees
365
Stock Exchange
NASDAQ
Ticker Symbol
AERI
Full Company Profile

Financial Performance

In 2020, AERI's revenue was $83.14 million, an increase of 18.96% compared to the previous year's $69.89 million. Losses were -$183.10 million, -8.26% less than in 2019.

Financial Statements

Analyst Forecasts

According to 13 analysts, the average rating for AERI stock is "Buy." The 12-month stock price forecast is 27.25, which is an increase of 61.91% from the latest price.

Price Target
$27.25
(61.91% upside)
Analyst Consensus: Buy